Biopharmaceutical company Appili Therapeutics Inc. announced that it will receive a $3 million grant from the U.S. Department of Defense to fund its AT1-1503 antibiotic program, which targets gram-negative ESKAPE pathogens.
ESKAPE pathogens — Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species — have become increasingly problematic in recent years because of the overuse of antibiotics in agriculture and clinical practices.
Image by David Mark from Pixabay
Read more at Healio…
The post DOD gives $3M grant to develop antibiotics for ESKAPE pathogens appeared first on Healthier Environment Living Program.